Transcriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways activated by the virus, proposes unique sex-specific differences and predicts tailored therapeutic strategies [0.03%]
SARS-CoV-2感染的转录景观拆解了病毒激活的病理性途径，提出了独特的性别特异性差异并预测了个性化的治疗策略
Paolo Fagone,Rosella Ciurleo,Salvo Danilo Lombardo et al.
Paolo Fagone et al.
The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) has posed a serious threat to global health. As no specific therapeutics are yet available to control disease evolution, more in-depth unde...
Fatal COVID-19 infections: Is NK cell dysfunction a link with autoimmune HLH? [0.03%]
新冠肺炎重症感染：NK细胞功能障碍与自身免疫性噬血细胞综合征相关吗？
Mohammed S Osman,Charmaine van Eeden,Jan Willem Cohen Tervaert
Mohammed S Osman
Piero Ruscitti,Onorina Berardicurti,Annamaria Iagnocco et al.
Piero Ruscitti et al.
How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion [0.03%]
新型冠状病毒肺炎大流行期间自身免疫性风湿和炎症性肠病患者的管理——专家意见
Piercarlo Sarzi-Puttini,Daniela Marotto,Marco Antivalle et al.
Piercarlo Sarzi-Puttini et al.
•A correct patient risk stratification is of paramount importance for the proper management of economic and human resources.•Clinical trials are crucial to assessing immunosuppressant prophylaxis and treatment to avoid overuse and treatme...
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy [0.03%]
托珠单抗治疗意大利布雷西亚严重COVID-19肺炎高炎症综合征及急性呼吸衰竭患者：一项针对100例患者的单中心研究
Paola Toniati,Simone Piva,Marco Cattalini et al.
Paola Toniati et al.
A hyperinflammatory syndrome (HIS) may cause a life-threatening acute respiratory distress syndrome (ARDS) in patients with COVID-19 pneumonia. A prospective series of 100 consecutive patients admitted to the Spedali Civili University Hospi...
Seven recommendations to rescue the patients and reduce the mortality from COVID-19 infection: An immunological point of view [0.03%]
从免疫学角度提出的7项建议：拯救新冠肺炎患者，减少死亡率
Andreas Kronbichler,Maria Effenberger,Michael Eisenhut et al.
Andreas Kronbichler et al.
Now COVID-19 is causing a severe public health emergency and the mortality is rapidly increasing all over the world. In the current pandemic era, although there have been many efforts to diagnose a number of patients with symptoms or close ...
Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia? [0.03%]
托珠单抗治疗COVID-19肺炎细胞因子风暴的风险与念珠菌血症风险增加有关吗？
Spinello Antinori,Cecilia Bonazzetti,Guido Gubertini et al.
Spinello Antinori et al.
SARS-CoV-2 infection among patients with systemic autoimmune diseases [0.03%]
系统性自身免疫性疾病患者的SARS-CoV-2感染
Giacomo Emmi,Alessandra Bettiol,Irene Mattioli et al.
Giacomo Emmi et al.
Objectives: This study aimed to evaluate the prevalence of clinically overt SARS-CoV-2 infection (COVID-19) among patients with systemic autoimmune diseases residing in Tuscany, and to compare it with that observed in the...
Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review [0.03%]
免疫调节疗法在重度COVID-19治疗中的作用。超越抗病毒疗法：全面综述
Jaume Alijotas-Reig,Enrique Esteve-Valverde,Cristina Belizna et al.
Jaume Alijotas-Reig et al.
Severe Acute Respiratory Syndrome related to Coronavirus-2 (SARS-CoV-2), coronavirus disease-2019 (COVID-19) may cause severe illness in 20% of patients. This may be in part due to an uncontrolled immune-response to SARS-CoV-2 infection tri...
Interleukin-17A (IL-17A), a key molecule of innate and adaptive immunity, and its potential involvement in COVID-19-related thrombotic and vascular mechanisms [0.03%]
白细胞介素-17A（IL-17A），一种固有免疫和适应性免疫的关键分子及其在COVID-19相关血栓形成和血管机制中的潜在作用
Federica Raucci,Adel Abo Mansour,Gian Marco Casillo et al.
Federica Raucci et al.